



US006376248B1

(12) **United States Patent**  
**Hawley-Nelson et al.**

(10) **Patent No.: US 6,376,248 B1**  
(45) **Date of Patent: \*Apr. 23, 2002**

(54) **PEPTIDE-ENHANCED TRANSFECTIONS**

(75) Inventors: **Pamela Hawley-Nelson**, Silver Spring; **Jianqing Lan**, Germantown; **PoJen Shih**, Columbia; **Joel A. Jesse**, Mt. Airy; **Kevin P. Schifferli**, Germantown; **Gulilat Gebeyehu**, Silver Spring; **Valentina C. Ciccarone**, Gaithersburg; **Krista L. Evans**, Germantown, all of MD (US)

(73) Assignee: **Life Technologies, Inc.**, Rockville, MD (US)

(\*) Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/039,780**

(22) Filed: **Mar. 16, 1998**

**Related U.S. Application Data**

(63) Continuation-in-part of application No. 08/818,200, filed on Mar. 14, 1997, now Pat. No. 6,051,429.

(51) **Int. Cl.**<sup>7</sup> ..... **C12N 15/88**; C12N 7/00; C12N 15/63; C12N 15/11

(52) **U.S. Cl.** ..... **435/458**; 435/320.1; 435/235.1; 536/23.1

(58) **Field of Search** ..... 435/235.1, 320.1, 435/458; 536/23.1

**(56) References Cited****U.S. PATENT DOCUMENTS**

4,897,355 A	1/1990	Eppstein et al. ....	435/240.2
4,946,787 A	8/1990	Eppstein et al.	
5,166,320 A	11/1992	Wu et al. ....	530/395
5,198,423 A	3/1993	Taguchi et al. ....	514/12
5,266,106 A	11/1993	Winnik et al. ....	106/22 K
5,334,761 A	8/1994	Gebeyehu et al. ....	564/197
5,338,532 A	8/1994	Tomalia et al. ....	424/1.49
5,354,844 A	10/1994	Beug et al. ....	530/345
5,527,524 A	6/1996	Tomalia et al. ....	424/1.33
5,532,142 A	7/1996	Johnston et al. ....	435/69
5,547,932 A	8/1996	Curiel et al. ....	435/65
5,560,929 A	10/1996	Hedstrand et al. ....	424/486
5,574,142 A	11/1996	Meyer, Jr. et al. ....	536/23.1
5,578,475 A	11/1996	Jesse .....	435/172.3
5,583,198 A	12/1996	Whittaker .....	530/345
5,587,441 A	12/1996	Frechet et al. ....	526/238
5,587,446 A	12/1996	Frechet et al. ....	526/3.33
5,589,392 A	12/1996	Short .....	435/320.1
5,631,329 A	5/1997	Yin et al. ....	525/417
5,658,776 A	8/1997	Flotte et al. ....	435/172.3
5,661,025 A	8/1997	Szoka, Jr. et al. ....	435/172.3
5,670,347 A	9/1997	Gopal .....	435/172.1

(List continued on next page.)

**FOREIGN PATENT DOCUMENTS**

AU	B-26526/92	9/1992
EP	0 304 111 B1	7/1988
EP	0 359 347 B1	8/1989
EP	0 359 347	3/1990
EP	0 544 292	11/1992
WO	WO 87/02061	4/1987
WO	WO 90/09786	9/1990
WO	WO 91/04753	4/1991
WO	WO 91/07947	6/1991
WO	WO 91/15501	10/1991
WO	WOA91/16024	10/1991
WO	WO92/13570	8/1992
WO	WO 92/21752	12/1992
WO	WO 92/22635	12/1992
WO	WO 93/05162	3/1993
WO	WO93/07282	4/1993
WO	WO 93/07283	4/1993
WO	WO93/19768	10/1993
WO	WO94/04696	3/1994
WO	WO94/23751	10/1994
WO	WO95/02397	1/1995
WO	WO95/17373	6/1995
WO	WO95/24221	9/1995
WO	WO95/31557	11/1995
WO	WO96/01841	1/1996
WO	WO96/05218	2/1996
WO	WO96/10038	4/1996
WO	96/15811	5/1996
WO	WO96/22321	7/1996
WO	WO96/22765	8/1996
WO	WO96/31549	10/1996

**OTHER PUBLICATIONS**

Behr, J.-P., "Synthetic Gene-Transfer Vectors," (1993) *Accounts of Chemical Research* 26:274-278.  
Citovsky, V. et al., "Nuclear localization of agrobacterium VirE2 protein in plant cells," (1992) *Science* 256:1802.  
Cotten, M. et al., "Transferrin-polycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels," (1990) *Proc. Natl. Acad. Sci.* 87:4033-4037.

(List continued on next page.)

**Primary Examiner—John S. Brusca****(74) Attorney, Agent, or Firm—Greenlee, Winner and Sullivan, P.C.****(57) ABSTRACT**

The present invention provides compositions useful for transfecting eukaryotic cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or dendrimer). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.